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Retinoic acid (RA), which is a vitamin A 
derivate,  has been used as a therapy 
against cancer thanks to its antiproliferative 
activity. The problem is that some cancers 
show resistance to the treatment, not even 
no effect, but also contrary actions, the 
overcoming of these actions would be very 
useful for therapy. We will study these 
functions and what determines if apoptotic 
or antiapoptotic action is found in the 
cancer[1]. 
RA Classical Pathway 
RA can be synthesized from retinol bound 
to cellular retinol-binding protein (CRBP) 
in the cytosol. RA binds cellular RA binding 
protein (CRABP) in cytosol and it drives RA 
to the nucleus, where it activates the 
receptors RXR-RAR dimmers that control 
different gene expression through RA 
response elements (RAREs), multiple co-
activators and co-repressors participate in 
the process[2]. 
RA Antiproliferative Activity 
 RA upregulates 
caspase 9 and p53 
expression and 
downregulates Bcl-2 
proteins, increasing 
apoptotic pathway, it 
also increases the 
expression of caspases 
3, 6 and 7, increasing 
the susceptibility to 
apoptosis. CRABP-II 
can also be involved, 
upregulating Apaf-1, 
the main component 
of the apoptosome[3]. 
  
RA also affects the extrinsic pathway. 
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Objective Introduction 
When the ratio 
between the  RA 
binding proteins 
CRABP-II/fatty acid 
binding protein 
(FABP5)  
is low, RA binds to 
PPARβ/δ rather 
than RAR. This 
receptor leads to 
the antiapoptotic 
action. PPARβ/δ 
upregulates target 
gene PDK1 and 
downregulates 
PTEN, resulting in 
an increase of cell 
survival pathways. 
This is the opposite 
effect of the typical 
pathway[4].  
 More knowledge about the RA target 
genes is still needed, this could provide 
new therapeutic targets. 
 The control of CRABP-II/FABP5 ratio 
could overcome the RA treatment 
opposite effects. Inhibitors or siRNA 
against FABP5 could be a good strategy. 
 Retinoic Acid treatment could be very 
useful and effective against some cancer 
types if the actions are completely 
understood and the current problems are 
solved.  
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The aim of this work is to make a 
review of the role of retinoic acid in 
cancer. Also to understand the 
problems of the  retinoic acid (RA) 
therapy used in many cancers.  
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